The Glassware Washing Facility (a CCSG Core since 1976) is a Cancer Center managed resource which provides cleaning and sterilization of reusable laboratory glassware, instruments and equipment and provides sterilization of biohazardous tissue culture waste from Center research laboratories. Routine services are washing, material wrapping/preparation for sterilization, pipette plugging, accomodating individual investigators' customized washing and preparation needs, centralized autoclaving for media and liquids and biohazardous material. The facility is located in the Bunting-Blaustein Cancer Research Building (CRB I) and services are provided by glassware washers supervised by the Laboratory Facilities and Services Manager. Service logs are maintained and each investigator is charged for these services. The newly upgraded facility is equiped with three washers, three autoclaves, two dryers and other assorted support equipment. Currently three glassware washing staff members process glassware, media and waste. In January 2006, this facility will provide support for Cancer Research Building II (CRB II), which will double the number of research investigators to whom the Core provides services. The existing facility has been recently renovated and has added one washer, one autoclave and one dryer. Casework has been added to increase and improve the efficiency of the prep/plugging area. There will also be one additional autoclave in CRBII to handle autoclaving of biohazardous waste. Two additional staff member will be added to handle the increased volumes from CRB II.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-46
Application #
7726515
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
46
Fiscal Year
2008
Total Cost
$52,682
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:

Showing the most recent 10 out of 2393 publications